Shilpa Medicare's subsidiary, Shilpa Biologicals, has signed a co-development and supply agreement with Finland's Orion Corporation for an intravenous Nivolumab biosimilar. Shilpa will exclusively manufacture the cancer immunotherapy, while Orion leverages its regional commercial infrastructure to market and distribute the product across Europe.
MUMBAI — Shilpa Medicare Limited announced on Tuesday, June 30, 2026, that its wholly owned subsidiary, Shilpa Biologicals Private Limited (SBPL), has entered into a definitive co-development and supply agreement with Orion Corporation. Headquartered in Finland, Orion Corporation is a globally recognized pharmaceutical innovator. The international contract centers on the collaborative creation and long-term manufacturing of an intravenous (IV) Nivolumab biosimilar, one of the world's most widely utilized oncology immunotherapies. The transaction marks a crucial validation of India’s biological manufacturing infrastructure, accelerating corporate penetration into high-barrier regulatory markets across the European continent.
Terms of the European Co-Development and Supply Deal
Under the formalized framework of the bilateral transaction, Shilpa Biologicals assumes full responsibility for the co-development, regulatory scale-up, and commercial manufacturing of the IV Nivolumab biosimilar. The Indian entity will serve as the exclusive production partner for the asset.
Concurrently, Orion Corporation will hold absolute, exclusive commercial rights to handle regional product registration, local marketing, field distribution, and direct sales activities across all major European territories. The deal is strategically structured to merge Shilpa's technical manufacturing and clinical development capabilities with Orion’s established commercial networks and hospital-generic market footprints. Nivolumab is structurally classified as a human programmed death receptor-1 (PD-1) blocking antibody, heavily prescribed to treat advanced melanomas, non-small cell lung carcinomas, and renal cell malignancies.
Strategic Capital Alignment and Corporate Growth
This commercial agreement follows an initial, highly successful strategic partnership forged between the two pharmaceutical majors in May 2025. That previous arrangement granted Orion exclusive European rights to distribute Shilpa’s Recombinant Human Albumin, an emerging plasma protein substitute. Expanding their alignment into advanced oncology biosimilars represents a major move up the global value chain for the Raichur-headquartered firm.
The continuous operational scaling arrives as Shilpa Medicare reports exceptionally robust financial performance. According to recent consolidated financial sheets filed for the 2025–26 fiscal period, the company's biologicals and formulations divisions recorded double-digit operational revenue expansions. Financial credit agencies have subsequently revised the company's long-term banking facility outlook to positive, citing strong earnings visibility from high-margin contract development and manufacturing organization (CDMO) agreements alongside steady backward integration efficiencies.
Impact on Global Patient Access and Healthcare Supply
The introduction of a certified biosimilar alternative for a high-cost oncology treatment like Nivolumab provides substantial financial relief to global healthcare networks:
Lower Healthcare Costs: Biosimilars introduce healthy market competition, helping European public healthcare administrators and private insurers drastically lower their annual oncology budgets.
Broader Patient Access: Lower per-dose market pricing allows medical centers to offer advanced immunotherapy lines to a much wider demographic of cancer patients.
Supply Chain Security: Leveraging specialized production facilities in India diversifies international medicine logistics, mitigating the risk of manufacturing bottlenecks or regional drug shortages.
Official Sources Section
The transaction details, statutory provisions, and execution protocols were formally communicated via regulatory disclosures submitted directly to the National Stock Exchange of India (NSE) and BSE Limited under Regulation 30 of the SEBI Listing Regulations. The corporate filings and historical biological milestones are documented in investor relation platforms managed by Shilpa Medicare Limited.
Quote Section
"Pursuant to Regulation 30 read with other applicable provisions of the SEBI Listing Regulations, we wish to inform that Shilpa Biologicals Private Limited (SBPL), a wholly owned subsidiary of Shilpa Medicare Limited, has entered into a Co-development and supply agreement with Orion Corporation," Ritu Tiwary, Company Secretary and Compliance Officer of Shilpa Medicare Limited, verified in a signed filing to the exchanges. "The agreement seamlessly combines Shilpa's manufacturing capabilities with Orion's commercial infrastructure".
Why It Matters
For global medical consumers and institutional purchasers, the formalization of this co-development pact ensures the long-term availability of highly regulated, affordable biosimilar alternatives for life-saving cancer therapies. For capital market participants, it cements Shilpa Medicare's status as an elite player in the specialized CDMO space. By consistently securing multi-year contracts with prominent European pharmaceutical conglomerates, the company successfully insulates its financial model from localized pricing pressures, establishing a stable runway for high-margin biological exports.
Key Facts at a Glance
The Partnership: Shilpa Biologicals and Orion Corporation sign a co-development and supply pact.
The Target Asset: Intravenous (IV) Nivolumab biosimilar, a widely used cancer immunotherapy.
Market Geography: Shilpa will handle exclusive manufacturing, while Orion secures exclusive European distribution.
Precedent Alliance: Builds directly upon an existing May 2025 European pact involving Recombinant Human Albumin.
Regulatory Gateway: Formally processed and declared via SEBI Listing Regulation compliance disclosures.
FAQ Section
What is Nivolumab and why is this biosimilar development significant?
Nivolumab is a highly effective, widely prescribed intravenous cancer immunotherapy used to treat severe conditions like melanoma and lung cancer. Developing a biosimilar version creates a highly equivalent, significantly more affordable version of the medicine, reducing costs for hospitals and patients.
What are the specific operational responsibilities of each company under this deal?
Shilpa Biologicals is solely responsible for co-developing, scaling up, and exclusively manufacturing the drug asset. Orion Corporation retains the exclusive rights to manage the clinical registration, marketing, branding, and sales logistics across all European markets.
Is Orion Corporation a related party or promoter group to Shilpa Medicare?
No. Official exchange filings confirm that Orion Corporation is an independent, international corporate entity based in Finland and does not share any structural or promoter cross-ownership with Shilpa Medicare or its internal subsidiaries.
Source: National Stock Exchange of India Corporate Disclosures, BSE Limited Corporate Announcements, Shilpa Medicare Limited Investor Relations Portal.
